Paper41239747
Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.
Catella CM and 10 others. Biotechnol Bioeng, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types. Papers, record 41239747. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41239747
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacterial Toxins | Major topic |
| Bacterial Proteins | Major topic |
| Clostridioides difficile | Major topic |
| Glucosyltransferases | Major topic |
| Peptides | Major topic |
| Enzyme Inhibitors | Major topic |
| Humans | |
| Anti-Bacterial Agents |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R56 AI177728 | NIAID NIH HHS | United States | R56AI177728 | PubMed | NIH RePORTER |
| T32 GM133366 | NIGMS NIH HHS | United States | T32GM133366 | PubMed | NIH RePORTER |
| National Institutes of Health; North Carolina Biotechnology Center; Novo Nordisk Fonden; National Science Foundation. | PubMed | PubMed |
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29617739 | Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/29617739 | PubMed |
| 2 | 24311789 | Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24311789 | PubMed |
| 3 | 19394704 | Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. | J Infect | 2009 | https://conductscience.org/library/papers/19394704 | PubMed |
| 4 | 31756084 | Discovery and Evaluation of Peptide Ligands for Selective Adsorption and Release of Cas9 Nuclease on Solid Substrates. | Bioconjug Chem | 2019 | https://conductscience.org/library/papers/31756084 | PubMed |
| 5 | 21231971 | Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. | Mol Microbiol | 2011 | https://conductscience.org/library/papers/21231971 | PubMed |
| 6 | 26862400 | Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. | Ther Adv Infect Dis | 2016 | https://conductscience.org/library/papers/26862400 | PubMed |
| 7 | 27680706 | Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. | Nature | 2016 | https://conductscience.org/library/papers/27680706 | PubMed |
| 8 | 32903430 | Human α-Defensin-5 Efficiently Neutralizes Clostridioides difficile Toxins TcdA, TcdB, and CDT. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32903430 | PubMed |
| 9 | 9312171 | Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells. | J Clin Invest | 1997 | https://conductscience.org/library/papers/9312171 | PubMed |
| 10 | 26037121 | Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections. | mBio | 2015 | https://conductscience.org/library/papers/26037121 | PubMed |
| 11 | 35058787 | Inhibition of Clostridioides difficile Toxins TcdA and TcdB by Ambroxol. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/35058787 | PubMed |
| 12 | 34882774 | Protease-stable DARPins as promising oral therapeutics. | Protein Eng Des Sel | 2021 | https://conductscience.org/library/papers/34882774 | PubMed |
| 13 | 29741092 | Advancing Peptide-Based Biorecognition Elements for Biosensors Using in-Silico Evolution. | ACS Sens | 2018 | https://conductscience.org/library/papers/29741092 | PubMed |
| 14 | 16344467 | Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16344467 | PubMed |
| 15 | 17901056 | Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding. | J Biol Chem | 2007 | https://conductscience.org/library/papers/17901056 | PubMed |
| 16 | 29180448 | A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells. | J Biol Chem | 2018 | https://conductscience.org/library/papers/29180448 | PubMed |
| 17 | 20863124 | Peptide inhibitors targeting Clostridium difficile toxins A and B. | ACS Chem Biol | 2010 | https://conductscience.org/library/papers/20863124 | PubMed |
| 18 | 32255488 | SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/32255488 | PubMed |
| 19 | 38717124 | Fecal microbiota transplantation: current challenges and future landscapes. | Clin Microbiol Rev | 2024 | https://conductscience.org/library/papers/38717124 | PubMed |
| 20 | 25451052 | Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25451052 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42291326 | A single amino acid substitution determines susceptibility of Clostridioides difficile toxin B variants to monoclonal antibody neutralization. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/42291326 | PubMed |
| 41991729 | Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin. | Arch Toxicol | 2026 | https://conductscience.org/library/papers/41991729 | PubMed |
| 41239747 | Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types. | Biotechnol Bioeng | 2026 | https://conductscience.org/library/papers/41239747 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41239747
GET https://conductscience.org/api/papers/v1/41239747/references?page=2